• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    THE VALENS COMPANY OBTAINS FINAL COURT ORDER APPROVING THE PROPOSED PLAN OF ARRANGEMENT WITH SNDL

    1/3/23 1:19:00 PM ET
    $SNDL
    $VLNS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    KELOWNA, BC, Jan. 3, 2023 /PRNewswire/ - The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) ("The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce today that the Ontario Superior Court of Justice (Commercial List) has granted a final order approving the previously announced plan of arrangement (the "Arrangement") with SNDL Inc. ("SNDL") under Section 192 of the Canada Business Corporations Act in accordance with the terms of the arrangement agreement between Valens and SNDL dated August 22, 2022.

    The Valens Company Logo (CNW Group/The Valens Company Inc.)

    Under the terms of the Arrangement, Valens' shareholders will receive, for each common share of Valens (each, a "Valens Share"), 0.3334 of a common share of SNDL (the "Offer Exchange Ratio"). Based on the closing price of the SNDL shares on the Nasdaq Capital Market (the "Nasdaq") as at August 19, 2022, the consideration represents an implied value of $1.26 per Valens Share (the "Implied Offer Price"), for total consideration of approximately $138 million.

    Completion of the Arrangement remains subject to certain other customary closing conditions as further described in the Arrangement Agreement, and, subject to the satisfaction or waiver of such closing conditions, the Arrangement is expected to be completed during January 2023.

    The Arrangement Agreement, including further information on the conditions precedent to completion of the Arrangement, is described in the management information circular and proxy statement of Valens dated October 24, 2022, which has been filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar and is available on Valens' website at www.thevalenscompany.com.

    About The Valens Company

    The Valens Company is a leading cannabis consumer products company, with significant expertise in manufacturing cannabinoid-based products and a mission to bring the benefits of cannabis to the world. Valens provides proprietary cannabis processing services and best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens' high-quality products are formulated for the recreational, health and wellness, and medical consumer segments and are offered across all cannabis product categories, with a focus on quality and product innovation. Valens also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to international markets through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, Valens continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences. Through Valens Labs, Valens is setting the standard in cannabis testing and research and development with Canada's only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.

    ABOUT SNDL INC. 

    SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL." SNDL is the largest private sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. SNDL is a licensed cannabis producer that uses state-of-the-art indoor facilities to supply wholesale and retail customers under a cannabis brand portfolio that includes Top Leaf, Sundial Cannabis, Palmetto, Spiritleaf Selects, and Grasslands. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the global cannabis industry. For more information on SNDL, please go to www.sndl.com. 

    Notice regarding Forward Looking Statements

    All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "plans", "expects", "scheduled", "trends", "forecasts", "future", "indications", "potential", "estimates", "predicts", "anticipate", "to establish", "believe", "intend", "ability to", or statements that certain actions, events or results "may", "should", "could", "would", "might", "will", or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, statements regarding the anticipated timing for completion of the proposed plan of arrangement involving The Valens Company and SNDL.

    The risks and uncertainties that may affect forward-looking statements include, among others, if and when the proposed plan of arrangement involving The Valens Company and SNDL. will be completed, the inability to meet Nasdaq's requirement to maintain a minimum bid price for the Valens Shares of at least US$1 for 10 consecutive business days during the applicable cure period or to comply with Nasdaq's other listing standards within the prescribed time period, which could result in the delisting of the common shares from Nasdaq, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-valens-company-obtains-final-court-order-approving-the-proposed-plan-of-arrangement-with-sndl-301712576.html

    SOURCE The Valens Company Inc.

    Get the next $SNDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNDL
    $VLNS

    CompanyDatePrice TargetRatingAnalyst
    SNDL Inc.
    $SNDL
    7/17/2024Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    The Valens Company Inc.
    $VLNS
    3/3/2022Market Perform → Underperform
    Raymond James
    More analyst ratings

    $SNDL
    $VLNS
    Financials

    Live finance-specific insights

    See more
    • SNDL Reports First Quarter 2025 Financial and Operational Results

      The Company Delivers Record Gross Margin and Positive Cash Flow; Announces Strategic Review of U.S. Platform and Listing Structure EDMONTON, AB, May 1, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the first quarter ended March 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference cal

      5/1/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL to Announce First Quarter 2025 Financial Results on May 1, 2025

      EDMONTON, AB, April 14, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2025 financial results for the period ended March 31, 2025, before market opens on Thursday, May 1, 2025. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on May 1, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/4ikuz377 ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), th

      4/14/25 4:30:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Reports Fourth Quarter and Full Year 2024 Financial and Operational Results

      The Company reports Record Full Year Net Revenue, Gross Profit and Gross Margin, as well as positive Cash Flow and Free Cash Flow  CALGARY, AB, March 18, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2024. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation and shareholder letter on its website, found at https://sndl.com. The Co

      3/18/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    $VLNS
    SEC Filings

    See more
    • SEC Form 6-K filed by SNDL Inc.

      6-K - SNDL Inc. (0001766600) (Filer)

      5/1/25 7:21:29 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by SNDL Inc.

      6-K - SNDL Inc. (0001766600) (Filer)

      4/30/25 7:55:52 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by SNDL Inc.

      6-K - SNDL Inc. (0001766600) (Filer)

      4/22/25 7:32:45 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    $VLNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SNDL
    $VLNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canaccord Genuity resumed coverage on SNDL Inc.

      Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

      7/17/24 12:19:57 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • Sundial Growers upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

      8/16/22 7:59:34 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • Sundial Growers upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Sundial Growers from Underperform to Market Perform and set a new price target of $0.70 from $0.60 previously

      5/3/22 7:19:03 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Reports First Quarter 2025 Financial and Operational Results

      The Company Delivers Record Gross Margin and Positive Cash Flow; Announces Strategic Review of U.S. Platform and Listing Structure EDMONTON, AB, May 1, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the first quarter ended March 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference cal

      5/1/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Launches Rise Rewards Loyalty Program

      EDMONTON, AB, April 22, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is excited to announce the launch of its highly anticipated Rise Rewards loyalty program, designed to help Value Buds customers save more, earn more, and get even more from every visit. Starting April 22, 2025, Rise Rewards will be available at all Value Buds locations in Alberta, Ontario, Saskatchewan, and Manitoba. "Our vision is always focused on the consumer experience, and our Rise Rewards program is an exciting tool to provide even more value for the Value Buds shoppe

      4/22/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL to Announce First Quarter 2025 Financial Results on May 1, 2025

      EDMONTON, AB, April 14, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2025 financial results for the period ended March 31, 2025, before market opens on Thursday, May 1, 2025. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on May 1, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/4ikuz377 ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), th

      4/14/25 4:30:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    $VLNS
    Leadership Updates

    Live Leadership Updates

    See more
    • SNDL Appoints New Chief Information Officer and New President, Liquor Division

      CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

      11/21/24 6:02:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Announces 2024 Annual General Meeting Results

      CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

      7/30/24 5:45:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • Skymint Assets Acquired from Receivership; Sunstream USA Builds on Parallel Acquisition

      CALGARY, AB, Oct. 13, 2023 /PRNewswire/ - SunStream Bancorp Inc. ("SunStream") is pleased to announce a receivership court order (the "Sale Order") granting the sale of certain assets of Greenpeak Industries Inc. and certain affiliated entities d.b.a. Skymint ("Skymint") to Skymint Acquisition Co. (the "Skymint Transaction"), a newly formed designee entity of Tropics LP ("Tropics"). Tropics is a limited partnership fully owned by an affiliate of Sunstream, a joint venture sponsored by SNDL Inc. (NASDAQ:SNDL) ("SNDL").  Skymint Acquisition Co. is anticipated to be part of the S

      10/13/23 8:37:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    $VLNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

      SC 13G/A - SNDL Inc. (0001766600) (Filed by)

      1/31/24 4:48:48 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

      SC 13G/A - SNDL Inc. (0001766600) (Subject)

      2/14/23 5:28:02 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

      SC 13G/A - SNDL Inc. (0001766600) (Filed by)

      2/13/23 4:06:09 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care